Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
The most recent EPS for Takeda Pharmaceutical Co Ltd is $-15.56, not beating expectations of $-24.25.
How did Takeda Pharmaceutical Co Ltd TAK's revenue perform in the last quarter?
Takeda Pharmaceutical Co Ltd revenue for the last quarter is $-15.56
What is the revenue estimate for Takeda Pharmaceutical Co Ltd?
According to 4 of Wall street analyst, the revenue estimate of Takeda Pharmaceutical Co Ltd range from $1228.08B to $1093.68B
What's the earning quality score for Takeda Pharmaceutical Co Ltd?
Takeda Pharmaceutical Co Ltd has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Takeda Pharmaceutical Co Ltd report earnings?
Takeda Pharmaceutical Co Ltd next earnings report is expected in 2026-08-11
What are Takeda Pharmaceutical Co Ltd's expected earnings?
Takeda Pharmaceutical Co Ltd expected earnings is $1132.05B, according to wall-street analysts.
Did Takeda Pharmaceutical Co Ltd beat earnings expectations?
Takeda Pharmaceutical Co Ltd recent earnings of $1094.54B does not beat expectations.